

ANNEXIN PHARMACEUTICALS TO PRESENT AT AKTIEDAGARNA IN STOCKHOLM ON JUNE 10

Annexin Pharmaceuticals AB (publ) today announces that the company will participate at Aktiedagarna in Stockholm on June 10, 2026, where CEO Anders Haegerstrand will give a company presentation and answer questions about the company's operations and plans for the future.

Presentation time: 2:45 PM CEST, Wednesday June 10, 2026

The presentation will be live-streamed and can be followed at: [Link to presentation](#)

Aktiedagarna is held at Birger Jarl Conference, Birger Jarlsgatan 61 A, Stockholm, 9–10 June 2026. For registration and programme, see: [Registration](#)

Welcome!

For further information, please contact:

Anders Haegerstrand, CEO

Phone: +46 (0)70 575 50 37

Mail: anders.haegerstrand@annexinpharma.com

About Annexin Pharmaceuticals AB

Annexin Pharmaceuticals is a clinical stage biotechnology company active in the therapeutic areas ophthalmology and oncology. The company develops ANXV, a recombinant human Annexin A5 protein, as a first-in-class biologic with potentially disease-modifying mechanisms of action. The ANXV program is currently in Phase 2 in ophthalmology for retinal vein occlusion (RVO) and diabetic retinopathy (DR) and in pre-clinical stage in oncology.

The company is based in Stockholm and listed on Nasdaq First North Growth Market Sweden under the ticker ANNX. Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments

[Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10](#)